ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 35

B-Cell Subset Differences in Inflammatory Rheumatic Diseases

Joao Lagoas Gomes1,2, Dario Ligeiro3, Alice Lima3, Cristina Teixeira3, Alexandre Sepriano4,5, Sofia Ramiro6, Carina Lopes7, Tiago Costa8, Manuela Costa8, Jaime Cunha Branco1,2 and Fernando Pimentel-Santos1,2, 1Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, 2CEDOC, NOVA Medical School, Lisbon, Portugal, 3Centro de Sangue e Transplantação de Lisboa, Instituto Português do Sangue e Transplantação (IPST), I.P, Lisbon, Portugal, 4CEDOC, NOVA Medical School, Lisboa, Portugal, 5Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 7Hospital de Egas Moniz-CHLO, Lisbon, Portugal, 8Rheumatology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cells, Immune Dysregulation and ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Targeting humoral immunity has been proved effective in several inflammatory rheumatic diseases (IRD). Though clinical trials have shown some efficacy of B-cell depletion in ankylosing spondylitis (AS), results are less convincing. Other studies have revealed an association between mutations and expression of immune regulatory genes suggesting a B-cell dysfunction in the development and progression of AS. Yet, there is still lack of data describing B-cell subsets in AS. The study purpose is to assess and compare the immature, naive and antigen differentiated subsets of peripheral B-cell compartment in AS with those in healthy controls (HC) and other IRD

Methods:  Patients with AS, RA and SLE according to respective classification criteria were included. Patients under biologic DMARDS were not included. Sociodemographic and clinical variables were recorded and blood samples were collected for quantification of inflammatory markers, immunoglobulin levels and assessment of B-cell immature transitional stages and mature subsets by flow cytometry. Mann-Whitney and Fisher´s exact test were used for statistical analysis

Results:  Overall, 60 patients and 12 HC were included. All patient groups presented similar and rather low levels of inflammation, as measured by CRP, ESR and immunoglobulins, in addition to a decreased lymphocyte count. There were no differences in the B-cell counts between AS patients and HC, and both groups had higher B-cell counts than RA and SLE patients. Regarding B-cell subsets, the immature transitional compartment of AS patients was found in normal range, but not in RA and SLE. The latter presented a significant decrease in all transitional cell maturity stages (T1-T3). The next step in B-cell differentiation is mature naïve cells, also found to be normal in AS and decreased in RA and SLE. AS patients presented slightly higher counts of CD27+IgD+ MZ-like and class able to switch memory cells with reference to HC and these cell numbers were found to be low in RA and SLE patients. Switched memory CD27+IgD- B-cells were reduced in all patient groups, however, only SLE patients presented highly decreased cell levels

Conclusion:  We found that while a severe dysfunction is present in the homeostasis of the B-cell compartment in RA and in particular SLE pts, which are lymphopenic in both immature and mature B-cell compartments, it appears that AS patients are not affected in the same way. At this stage, functional studies appear to be necessary in order to identify differences in key mechanisms of B cell development and differentiation that play a role in the aetiology and progression of these inflammatory rheumatic diseases. Our first results, however, establish that pathophysiological mechanisms involving B-cells clearly differentiate AS from RA and SLE

 

AS

(n=22)

RA

(n=20)

SLE

(n=18)

HC

(n=12)

Male, Female; n (%)

11 (50); 11 (50)

9 (45); 11 (55)

5 (27.8); 13 (72.2)

3 (25); 9 (75)

Age; median (IQR)

56 (45.8-65.5)

55 (51-65.5)

44 (37.5-52.5)*

56 (35.3-63.3)

ESR mm/hour

14 (10-29.3)

21 (10.3-37.8)

23 (6-34.5)

11 (8-22.5)

CRP mg/dL

1.1 (0.9-1.7)

0.98 (0.7-3.2)

0.6 (0.5-1.6)

–

HLA B27+: n (%)

11 (68.8)

–

–

–

With csDMARS, n (%)

6 (30)

18 (90)

15 (83.3)

0

Ig seric levels, mg/dl; median (IQR)

IgG

1165 (881.3-1247.5)

1021 (830.3-1265)

1140  (1003-1325

1033.5 (823.3-1235)

IgA

230 (158.8-340)

250.5 (164.3-315.3)

261 (205-323)

236.5 (150.3-339.8)

IgM

95.3 (65.6-119.5)

112 (67.7-164.8)

103 (60.6-131.5

122 (71.5-158.3)

Absolute cell counts/μl blood; median (IQR)

Lymphocytes

1685 (1217-2007.5)

1555 (1097.5-2085)

1250 (625-1892.5)

2170 (1830-2377)**

Total B-cells (CD20+)

186.3(111-238.6)

96.2 (50.3-180.6)***

65.8 (20.9-116.1)***

182.1 (100.9-269.7)

Immature Transitional B-cells (CD5+CD27–IgD+), median (IQR)

CD24+++CD38+++(T1)

2.8 (1.8-3.9)

0.6 (0.1-2.7)**

1.5 (0.2-2.8)**

4.3  (2.3-6.5)

CD24++CD38++(T2)

8.3 (5.1-14.9)

2.6 (0.2-8.0)**

3.0 (1.0-8.0)**

13.7 (5.7-18.8)

CD24+CD38+(T3)

9.0 (5.5-17.7)

2.2 (0.3-4.6)**

1.9 (0.2-3.7)**

7.7 (4.1-12.3)

Mature B-Cells, median (IQR)

CD27–IgD+ (naïve)

73.2 (49.7-121.7)

40.1(19.2-76.9)**

27.2(11.9-57.1) †

78.6 (48.4-163.4)

CD27+IgD+(mem. MZ-like)

25.9 (13.6-39.9)

13.0 (3.5-27.2)**

2.6 (1.8-9.6) †

18.9 (11.2-27.1)

CD27+IgD–(switch mem.)

18.8 (12.2-37.9)

13.5 (3.9-37.6)

4.9 (2.2-17.2)***

29.3 (14.51-37.9)

CD27–IgD–(double neg.)

2.4 (1.8-5.2)

3.1 (2.0-6.4)

2.9 (1.0-5.0)

5.2 (2.6-8.1)

Mann-Whitney and the Fisher´s exact test were used for comparison between AS and other groups

* p<0.05; **p<0.02; ***p<0.01; †p<0.0001;

 


Disclosure: J. Lagoas Gomes, None; D. Ligeiro, None; A. Lima, None; C. Teixeira, None; A. Sepriano, None; S. Ramiro, None; C. Lopes, None; T. Costa, None; M. Costa, None; J. C. Branco, None; F. Pimentel-Santos, None.

To cite this abstract in AMA style:

Lagoas Gomes J, Ligeiro D, Lima A, Teixeira C, Sepriano A, Ramiro S, Lopes C, Costa T, Costa M, Branco JC, Pimentel-Santos F. B-Cell Subset Differences in Inflammatory Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/b-cell-subset-differences-in-inflammatory-rheumatic-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cell-subset-differences-in-inflammatory-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology